Participated · Series A · Nov 2025

Qorium is a Dutch biotechnology company that engineers real leather by cultivating a small sample of animal cells, eliminating the need for livestock farming. The process yields uniform, high-performance leather while sharply reducing waste and environmental impact compared with conventional hides. Based in Maastricht, the firm is now installing larger bioreactor systems in its facilities and has already secured several commercial partnerships to bring its material to market. Management claims the product outperforms traditional leather on consistency and sustainability metrics. Prior to its latest raise, the company had attracted €8 million in seed funding to prove out its science. The new capital will allow Qorium to scale production, expand its team, and move closer to full commercialisation. Investors cite the technology’s potential to transform one of the world’s most polluting industries as a key driver of their support.

Led · Equity · Jul 2025

Novenda Technologies develops a full-stack multi-material 3D printing platform that produces single-piece dental products combining hard and soft materials, using water-soluble supports and proprietary software and materials. Its LD100 printer prints up to 15 nightguards and 8 dentures per hour and works exclusively with Novenda’s own materials, creating recurring consumables revenue. The company has eliminated mechanical rollers with smart print modes and uses a colour-management algorithm to achieve wide colour ranges while preserving mechanical properties. Novenda was founded in 2019 and built a team of fifteen experts across physics, chemistry, material science, and software engineering, with multiple patents filed. Early industry feedback praised surface finish and aesthetics, and the company achieved its first multi-material print in 2021 and proof of concept for nightguards and dentures in 2023. Novenda plans to expand into additional dental applications and scale deployments in mid-size and large dental labs across Europe and the US.

Led · Equity · May 2025

Hy2Care develops CartRevive, a proprietary hydrogel implant designed to repair damaged cartilage in a minimally invasive way. The company recently received FDA Investigational Device Exemption (IDE) approval to begin clinical evaluation of CartRevive in the U.S. Hy2Care has raised new capital to prepare for a U.S. clinical trial and to support early commercialisation steps in Europe and other global markets. The €4.5M financing comes as the firm positions itself within a growing regenerative orthopaedics market; the U.S. cartilage repair market is projected to exceed $1.6 billion by 2030. Investors include the European Innovation Council (EIC) Fund, existing shareholders led by Brightlands Venture Partners, and new participation from regional development agency LIOF.

Participated · Series A · Aug 2024

PL BioScience GmbH is a cell culture solutions provider that produces human platelet lysate (HPL) under safe and reproducible conditions. HPL is a growth-factor–rich supplement used to support cell growth and expansion for applications such as cell therapy and tissue engineering. The company offers advanced 2D and 3D cell culture solutions based on human platelet lysate and provides integrated smart hardware solutions. PL BioScience completed a €7.8M Series A financing. The round attracted new investors and secured continued support from existing backers. The financing underscores investor interest in standardized HPL-based culture systems.

Participated · Equity · Jan 2024

Matisse Pharmaceuticals is a clinical-stage Dutch company developing M6229, a non-anticoagulant fraction of heparin intended to neutralize toxic circulatory histones in sepsis patients. The company says neutralising cationic histones with M6229 inhibits the self-enforcing cascade that can lead to rapid organ failure; preclinical results have shown this inhibitory effect. Matisse recently secured €3.6M in a fresh funding round from Brightlands Venture Partners, private investment companies, informal investors, and the management team to support development. The financing will allow preparation for a large-scale phase II study and cover the planned full execution of phase II clinical trials. By 2024 the company aims to complete its Series A to fund scaling up production to commercial level and advance various R&D projects. Matisse plans to announce results of its phase 1/2a Histoseps trial in sepsis patients, which it describes as a major milestone. The company was founded in 2014 and is based in Geelan in the Netherlands.